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ABSTRACT
Objectives In developed countries, the incidence of 
colorectal cancer (CRC) has declined in the over 50 years 
age group but increased in younger people. We studied 
CRC incidence by age and the influence of screening 
uptake.
Design Age- standardised and sex- standardised 
incidences for CRC from 1997 to 2017 were obtained from 
the Scottish Cancer Registry (SCR). In addition, linkage 
between the Scottish Bowel Screening Database and the 
SCR allowed investigation of any association between 
screening participation and CRC incidence.
Setting Scotland and the Scottish Bowel Screening 
Programme, in which guaiac faecal occult blood test 
screening was piloted from March 2000 and fully rolled by 
December 2009.
Participants From the introduction of screening in 2000 
through to 2017, 2 395 172 were invited to participate, of 
whom 1 487 999 participated at least once.
Main outcome measures Incidence of CRC.
Results In the screening age range (50–74 years), CRC 
incidence peaked at 156.5 cases per 100 000 in 2010 
after full roll- out of screening across Scotland but fell to 
123.9 per 100 000 in 2017. However, under 50 years, 
there was a rise from 5.3 cases per 100 000 in 2000 to 6.8 
per 100 000 in 2017. When CRC incidence was examined 
in those who had been offered screening, incidence fell 
in the participant group more than in the non- participant 
group after roll- out of screening was complete. Analysis of 
cumulative incidence demonstrated that CRC incidence in 
the participant group remained consistently below that of 
the non- participant from around 7 years of follow- up.
Conclusions The incidence of CRC in Scotland has 
declined in the over 50 years age group but increased in 
younger people. It is likely that population screening has 
contributed to the reduction in CRC incidence in the over 
50 years age group.
INTRODUCTION
Colorectal cancer (CRC) is a major health 
problem worldwide. In Scotland, it is 
currently the third most commonly diagnosed 
non- cutaneous cancer and the second most 
common cause of cancer- related deaths.1 
However, the incidence of CRC varies widely 
across the world and it is estimated that 60% 
of CRC deaths occur in those countries with a 
high or very high Human Development Index 
(HDI).2 Western lifestyle factors, including 
obesity, lack of physical exercise, a diet rich in 
red and processed meat, smoking and alcohol, 
have all been linked to the risk of developing 
CRC,3 and marked increases in both inci-
dence and mortality have been observed in 
many medium–high HDI countries, espe-
cially in Asia, South America and Eastern 
Europe.2 However, both incidence and 
mortality have either stabilised or declined in 
countries with the highest HDI, for example, 
Australia, New Zealand, the USA and several 
western European countries.4 These reduc-
tions in mortality are likely to be attributable 
to improved access to high- quality treatment 
and earlier diagnosis through both screening 
and through prompt investigation of those 
presenting with symptoms.
The declines in incidence are not so easy 
to explain, especially since the frequency 
of obesity continues to rise in all high HDI 
Strengths and limitations of this study
 ► We examine age- standardised and sex- standardised 
incidence data for colorectal cancer (CRC) for the 
years 1997–2017 obtained from the Scottish Cancer 
Registry and linkage between the Registry and the 
Scottish Bowel Screening Database.
 ► We are able to show previously unreported changes 
in the incidence of CRC in Scotland in all age groups.
 ► We are able to examine in detail, for the first time, 
if population- based screening using faecal occult 
blood test is associated with incidence of CRC.
 ► Associations between incidence and plausible rea-
sons for the changes over time will help the devel-
opment of future interventions.
 ► Although this was a large study, we did not examine 
incidence by yearly age, only in three large groups.
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countries.5 However, there is now good evidence, largely 
from the USA and particularly from the Surveillance, 
Epidemiology and End Results Database that, while inci-
dence has been falling since around 1985 in those aged 
50 years and over, it has been rising in those under 50 
years since the mid- 1990s.3 In a recent analysis of inci-
dence and mortality databases from 39 countries, it was 
confirmed that countries with the highest HDI had a 
decrease in CRC incidence, but that incidence of colon 
and rectal cancers has continued to increase in countries 
with medium–high HDI, and in younger populations.6 It 
has been postulated that screening may be responsible 
for the reduction in incidence in the group aged over 50 
years, especially where this is associated with high rates of 
large bowel endoscopy, which facilitates the diagnosis and 
removal of pre- malignant adenomas.3 Since there is now 
robust evidence from randomised trials of endoscopic 
screening that removal of adenoma leads to a reduction 
in CRC incidence,7 this is an attractive hypothesis, but 
one that is difficult to test.
In Scotland, CRC screening, initially using biennial 
guaiac faecal occult blood tests (gFOBT), was rolled out 
to the whole of the population aged 50–74 years in 2007 
after a three screening rounds pilot which started in 
2000.8 9 In addition, Scotland, along with the rest of the 
UK, is ranked as having a very high HDI,2 and although 
the incidence has fallen by 18.6% from 2007 to 2017,1 
it still has a high incidence of CRC,1 and lifestyle factors 
associated with CRC are prevalent in the population.10 
We therefore examined the incidence of CRC between 
1997 and 2017 in the 50–74 years screening age range, 
the post- screening age range and the pre- screening age 
range. In addition, the effect of screening participation 
on CRC incidence was assessed.
METHODS
In Scotland, screening for CRC using biennial gFOBT, 
offered to everyone in the 50–69 years age range and 
registered with a general practitioner, commenced in 
March 2000 with a pilot involving three of the fourteen 
National Health Service (NHS) Boards responsible for 
routine healthcare. Roll- out to the rest of Scotland began 
in July 2007 and was completed by December 2009. The 
age range was also extended up to age 74 years for the 
whole of Scotland during roll- out. Details of the pilot, 
roll- out and descriptions of the screening algorithms 
have been published previously.8 9 Data are collected 
centrally by the Information Services Division of NHS 
National Services Scotland and held in the Scottish Bowel 
Screening Database (SBSD).
To assess changes in the incidence of CRC in different 
age ranges around the time of the introduction of 
screening, data were obtained from the Scottish Cancer 
Registry (SCR) for the years 1997–2017. Crude incidence 
rates were calculated by sex and 5- year age group using 
midyear population estimates from the National Records 
of Scotland (NRS). These rates were then directly 
standardised using the 2013 European Standard Popu-
lation. Age–sex standardised rates were calculated sepa-
rately for the screening (50–74 years), post- screening (75 
years and higher) and pre- screening (under 50 years) age 
ranges. Age–sex standardised CRC mortality rates were 
also calculated for the screening (50–74 years) and pre- 
screening (under 50 years) age ranges using death regis-
tration data from NRS.
To investigate the impact of screening participation 
on incidence, linkage was carried out between the SBSD, 
the SCR and NRS deaths. The SBSD allowed identifica-
tion of those invited for screening and those who partic-
ipated. Participants who received a positive or negative 
screening test result at any point were included in the 
participant cohort. Those who did not receive a positive 
or negative test result, or never returned a completed 
test, were included in the non- participant cohort. Data 
were included from the pilot through national roll- out, 
with the data on invites available from March 2000. 
Linkage with the SCR allowed CRC incidence to be calcu-
lated for the participant and non- participant groups and 
linkage with the NRS deaths records allowed removal of 
participants from study at the point of death. Follow- up 
data were available on 31 December 2017. Age–sex stan-
dardised rates were calculated for participant and non- 
participant groups as described above.
The age structure of the screening population changed 
a great deal in the early years of the study period (see 
online supplemental table 1). The ageing of the original 
pilot cohort, in addition to the expansion of the age- range 
on national roll- out, influences the annual CRC incidence 
rate, despite adjustment through standardisation. In addi-
tion, any reduction seen in annual CRC incidence could 
be influenced by a shortening time to diagnosis. That is, 
since cancers are detected earlier, the years after roll- out 
see a reduction in incidence exclusively due to early 
detection rather than to prevention of disease. To better 
analyse these issues, time- to- event analysis was used in 
addition to the descriptive time- series analysis. This facil-
itated better understanding of the relationship between 
participation in screening and how it affects an individ-
ual’s risk over time. Cumulative incidence was estimated 
using the Kaplan- Meier method. Cox regression was also 
used to estimate the impact of screening participation on 
time from invite to CRC diagnosis, adjusting for age at 
first invite, sex and level of socioeconomic status as deter-
mined by the Scottish Index of Multiple Deprivation.
An underlying assumption of Cox regression is that of 
proportional hazards, that is, that the ratio of the hazards 
between treatment and non- treatment groups remains 
constant over time. This assumption was not met for 
the participation status variable, since the CRC hazard 
increases at biennial intervals for the participant group, 
consistent with screening participation. In consequence, 
an alternative analytical approach is also presented, with 
separate HRs reported for less than, and more than, 
7 years of follow- up. Seven years was chosen as the cut- off 
because participant cumulative incidence is consistently 
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lower than non- participant (and the proportional 
hazards assumption is met) from this point. All analyses 
were performed using R statistical software, V.3.5.1 and 
95% CIs are shown as bars in the figures, when relevant.
Neither patients, participants in screening, nor the 
public were involved in any way in development of the 
research question, the design of the study, or any other 
aspect of this research. Dissemination to these groups is 
not possible nor applicable.
RESULTS
A total of 77 262 CRCs were diagnosed in Scotland between 
1997 and 2017. From the introduction of screening in 
2000–2017, 2 395 172 individuals were invited to partici-
pate (409 255 in the pilot, 1 985 917 in the programme), 
of whom 1 487 999 participated at least once. There were 
24 817 CRCs diagnosed within the population invited to 
screen (15 663 in participants, 9154 in non- participants) 
in the same period. These CRCs were detected through 
both screening and non- screening pathways.
In the 50–74 years (screening) age range, a slight drop 
in incidence was observed, from 154.4 cases per 100 000 in 
2000, the first year of the demonstration pilot, to 137.8 in 
2006. Then, coinciding with commencement of roll- out 
of screening across the country in 2007, an increase was 
noted, which peaked at 156.5 cases per 100 000 in 2010 
and began to fall to levels well below those seen in the 
immediate pre- screening period, reaching 123.9 per 
100 000 in 2017 (figure 1). In those aged 75 years and 
over (post- screening), a consistent drop in incidence was 
noted from 2009 (432.5 per 100 000) to 2017 (366.8 per 
100 100) (figure 2) whereas, in those aged under 50 years 
(pre- screening) a rise throughout the study period from 
5.3 cases per 100 000 in 2000 to 6.8 per 100 000 in 2017 
was seen, although with fluctuations (figure 3).
When CRC incidence in the population who had been 
offered screening was examined, there was a distinct 
difference between those who had participated at least 
once and those who never participated. The data shown 
are age and sex standardised since these variables influ-
ence both CRC incidence and uptake of screening, with 
both uptake and incidence increasing with age, and with 
uptake being lower, but incidence higher, in men than in 
women.11 Figure 4 shows that incidence increased more 
Figure 1 Age–sex standardised colorectal cancer incidence, ages 50–74 years, from 1997 to 2017 (95% CIs shown).
Figure 2 Age–sex standardised colorectal cancer incidence, ages 75 years and over, from 1997 to 2017 per 100 000 person- 
years (95% CIs shown).
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in the participant group than in the non- participant 
group as national roll- out of screening started but that, 
after roll- out had been completed, incidence fell in the 
participant group to a greater extent than in the non- 
participant group, with participant incidence 13.9% 
below non- participant in 2017. The large increase in inci-
dence in 2005 was due to there being no invitees in the 
over 75 years age range prior to this point (see online 
supplemental table 2). Since the CRC risk in the over 75 
years age range is higher than in those aged below 75 
years, the age- standardised rates are influenced by this 
ageing of the invited population.
Analysis of cumulative incidence shown in figure 5 
demonstrates the risk of developing CRC over time. 
Fluctuations can be seen initially in the participant 
group, consistent with the biennial screening interval. 
The participant group then remains consistently below 
that of the non- participant group from around 7 years 
of follow- up. Cox regression analysis adjusted for age at 
first invite, sex and socioeconomic deprivation gave an 
HR of 0.92 for participants, relative to non- participants 
(95% CI: 0.90–0.95, p<0.001). The HRs, when separating 
the follow- up period at 7 years, were 0.95 (95% CI: 0.92–
0.98, p<0.001) in the period up to 7 years and 0.87 (95% 
CI: 0.83–0.91, p<0.001) in the period 7 years or more. 
These data are shown separately for men and women in 
online supplemental figure 1.
We also examined mortality in the 50–74 years 
(screening) and the under 50 years (pre- screening) age 
groups. These data, with 95% CI, are given as online 
supplemental figures 2 and 3, and show a substantial 
reduction in mortality since the introduction of screening 
in the 50–74 years range, but not in the under 50 years 
range.
DISCUSSION
Statement of principal findings
The findings in this study have similarities with those 
reported in from other high- income countries,4 6 namely 
that the incidence of CRC is falling in older age groups but 
increasing in people under the age of 50 years. However, 
Figure 3 Age–sex standardised colorectal cancer incidence, ages less than 50 years, from 1997 to 2017 per 100 000 person- 
years (95% CIs shown).
Figure 4 Age–sex standardised colorectal cancer incidence for the screening population per 100 000 person- years, by 
screening participation status (95% CIs shown).
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in this study, we were not only able to examine the changes 
in CRC incidence by age, but also by screening partici-
pation, and this demonstrated, for the first time to our 
knowledge, that the fall in incidence was more evident in 
those who had participated in screening.
Strengths and weaknesses in relation to other studies
The Minnesota randomised controlled trial (RCT), 
which employed mostly rehydrated Hemoccult 
II giving a positivity of 9.8 %, did demonstrate a 
modest reduction in the groups offered screening 
after 18 years of follow- up,12 but the Nottingham 
RCT, which used gFOBT in un- rehydrated form (the 
same approach that was adopted in Scotland) and 
reported a 2% positivity, showed no effect on CRC 
incidence after 11 years.13 Overall, previous studies 
of the effect of gFOBT screening on CRC incidence 
have not shown a substantial effect. In Scotland, from 
December 2009, biennial gFOBT screening was being 
offered to the whole of the eligible population. This 
resulted in a positivity of around 2%, so that, with an 
average uptake at this time of 55%, only around 1% 
of people being offered screening actually underwent 
colonoscopy.9 Of those that did, the average positive 
predictive value of gFOBT for CRC was 10% and 40% 
for adenoma,9 so that less than 0.5% of the popula-
tion offered screening (the 50–74 years age range) 
would have had removal of adenoma. However, in 
the present study, the groups were much bigger than 
in the RCT and the reduction in incidence seen in 
the 50–74 years age range is likely to have been due, 
at least in part, to polypectomy following a positive 
screening test result. The rise in incidence imme-
diately after roll- out and preceding the consistent 
fall is likely to have been due to the well- described 
screening effect caused by a combination of early and 
overdiagnosis.14 This would not explain the later fall 
in incidence, however, since the incidence of disease 
after the introduction of screening tends not to fall 
back to baseline because of overdiagnosis (ie, some 
people with screen- detected disease would have never 
presented clinically) as is the case in breast cancer 
screening.15
It could be argued that a fall in incidence would 
not necessarily translate into a fall in mortality, if only 
indolent cancers were being prevented. However, this 
is highly unlikely, given that the fall in incidence seen 
in the flexible sigmoidoscopy screening trials was 
accompanied by reductions in mortality.7 In addition, 
just as North America, Oceania and most European 
countries,6 CRC mortality in the 50–74 years age range 
in Scotland has fallen over time and it is likely that 
part of this effect can be attributed to early detection 
and prevention of disease as a result of screening.16 It 
is also interesting that we did not observe a fall in CRC 
mortality in the under 50 years age range, lending 
further strength to the argument that screening has 
contributed to this trend.
Meaning of the study
In November 2017, the Scottish Bowel Screening 
Programme changed the screening test from gFOBT 
to a quantitative faecal immunochemical test (FIT) 
at a threshold of 80 µg haemoglobin/g faeces. At 
this threshold, in the first year of screening with FIT, 
there was a 100% relative increase in the number of 
participants with adenomas identified,17 so that, going 
forward, screening using FIT can be expected to bring 
about a greater reduction in CRC incidence than has 
been seen to date and this will be examined when 
the data become available. The other very important 
consideration is the increase in CRC incidence seen 
in younger people. One approach to this could be to 
extend screening to those aged under 50 years, but 
it must be borne in mind that, under the age of 50 
years, although incidence is increasing,18 it is still 
much lower than in the current screening age range.
Figure 5 Cumulative colorectal cancer incidence, by screening participation status.
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Unanswered questions and future research
There is no objective evidence yet to support screening 
under the age of 50 years, and other approaches, 
including improved awareness of symptoms, increased 
use of FIT to triage patients presenting in primary 
care with symptoms19 and addressing lifestyle issues 
in the Scottish population must be part of the solu-
tion. The reasons underlying the marked increase in 
incidence in those aged under 50 years are not clear, 
but may relate to lifestyle factors, particularly around 
diet, body weight and physical activity, all of which are 
associated with increased risk of CRC.20 Rising rates 
of obesity in younger life (which are indicators of diet 
and physical activity) are of particular interest, because 
excess adiposity is now experienced by more people at 
earlier life stages and a recent study has demonstrated 
a relationship between body mass index in childhood 
and risk of adult CRC.21 We cannot necessarily screen 
our way out of this problem.
Observational data such as these cannot prove defin-
itively that screening is the only cause of reduced inci-
dence. Over the age of 50 years, individuals are much 
more likely to undergo colonoscopy because of lower 
bowel symptoms than those under 50 years, and this may 
explain at least part of the incidence reduction in those 
aged over 50 years. It is interesting that, in the over 75 
years age range, a consistent decline in incidence was 
seen from 2009 onwards. Some of this cohort will have 
had the opportunity to return screening tests, but by no 
means all, and it is likely that colonoscopy for the inves-
tigation of symptoms is performed even more frequently 
in this age range.
However, the clear separation of yearly and cumu-
lative incidence by participation in screening lends 
persuasive evidence to the hypothesis that screening is 
at least in part responsible for the observed incidence 
patterns in the population. It could still be argued 
that the people who participated in screening were 
healthier than those who did not, and that lifestyle 
factors were also responsible for this observation but, 
given the clear effect of removal of adenomas on CRC 
incidence,7 it is highly likely that screening played an 
important role.
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